MX384569B - Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina - Google Patents
Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepinaInfo
- Publication number
- MX384569B MX384569B MX2018008653A MX2018008653A MX384569B MX 384569 B MX384569 B MX 384569B MX 2018008653 A MX2018008653 A MX 2018008653A MX 2018008653 A MX2018008653 A MX 2018008653A MX 384569 B MX384569 B MX 384569B
- Authority
- MX
- Mexico
- Prior art keywords
- azepine
- pyrido
- dopamine
- tetrahydro
- ligands
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- QIBPEANLJGMFBP-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine Chemical compound C1CNCCC2=CC=CN=C21 QIBPEANLJGMFBP-UHFFFAOYSA-N 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract 1
- 208000015891 sexual disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención proporciona compuestos de Fórmula I: (ver formula) y sales farmacéuticamente aceptables de los mismos en donde las variables R1, R2, R3, R4, R5, a y A son como se definen en la presente; procesos para la preparación de; intermedios utilizados en la preparación de; y composiciones que contienen dichos compuestos o sales, y sus usos para tratar trastornos mediados por D3 (o asociados con D3) que incluyen, por ejemplo, adicción a sustancias, abuso de sustancias, esquizofrenia (por ejemplo, sus síntomas cognitivos), deterioro cognitivo (por ejemplo, deterioro cognitivo asociado con esquizofrenia, AD o PD), enfermedad de Parkinson, manía, ansiedad, trastornos del control de impulsos, trastornos sexuales y depresión.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662279037P | 2016-01-15 | 2016-01-15 | |
| PCT/IB2017/050094 WO2017122116A1 (en) | 2016-01-15 | 2017-01-09 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018008653A MX2018008653A (es) | 2018-12-10 |
| MX384569B true MX384569B (es) | 2025-03-14 |
Family
ID=57838441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008653A MX384569B (es) | 2016-01-15 | 2017-01-09 | Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10590128B2 (es) |
| EP (1) | EP3402796B1 (es) |
| JP (1) | JP6929857B2 (es) |
| KR (1) | KR102206321B1 (es) |
| CN (1) | CN108884093B (es) |
| AU (1) | AU2017208119B2 (es) |
| BR (1) | BR112018013955B1 (es) |
| CA (1) | CA3011201C (es) |
| ES (1) | ES2837018T3 (es) |
| IL (1) | IL260298B (es) |
| MX (1) | MX384569B (es) |
| RU (1) | RU2712455C1 (es) |
| SG (1) | SG11201805202VA (es) |
| TW (1) | TWI633104B (es) |
| WO (1) | WO2017122116A1 (es) |
| ZA (1) | ZA201803776B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6929857B2 (ja) | 2016-01-15 | 2021-09-01 | ファイザー・インク | 6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド |
| EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
| CA3089498A1 (en) | 2018-01-26 | 2019-08-01 | Shionogi & Co., Ltd. | Condensed ring compounds having dopamine d3 receptor antagonistic effect |
| CN108997287B (zh) * | 2018-07-23 | 2021-12-28 | 陕西师范大学 | 以四氟硼酸的离子液体为氟源催化合成4-氟代四氢吡喃衍生物的方法 |
| CN109608451A (zh) * | 2018-12-17 | 2019-04-12 | 上海药明康德新药开发有限公司 | 一种2-氧亚基-吡啶并[2,3-d]氮杂卓-7(2H)-甲酸叔丁酯合成方法 |
| US20250186369A1 (en) * | 2022-03-07 | 2025-06-12 | Drexel University | Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US20050090485A1 (en) * | 2002-02-13 | 2005-04-28 | Bromidge Steven M. | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders |
| WO2003068732A2 (en) | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds |
| EP1661889A4 (en) | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| US8207160B2 (en) | 2003-12-18 | 2012-06-26 | Abbott Gmbh & Co. Kg | Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor |
| US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| GB0412314D0 (en) | 2004-06-02 | 2004-07-07 | Glaxo Group Ltd | Compounds |
| UA91341C2 (ru) * | 2004-07-15 | 2010-07-26 | Амр Текнолоджи, Інк. | Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
| EA200701856A1 (ru) | 2005-04-01 | 2008-02-28 | Уорнер-Ламберт Компани Ллс | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении |
| WO2007028132A2 (en) | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS |
| US7897595B2 (en) | 2006-05-26 | 2011-03-01 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| WO2008009125A1 (en) * | 2006-07-20 | 2008-01-24 | Cascade Therapeutics Inc. | Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands |
| GB0619176D0 (en) | 2006-09-29 | 2006-11-08 | Lectus Therapeutics Ltd | Ion channel modulators & uses thereof |
| MX2009004426A (es) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
| GB0710844D0 (en) | 2007-06-06 | 2007-07-18 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| EP2179385A2 (en) | 2007-07-09 | 2010-04-28 | Technion Research & Development Foundation Ltd. | Routing methods for multiple geographical entities |
| WO2009079765A1 (en) * | 2007-12-21 | 2009-07-02 | Cascade Therapeutics Inc. | Compounds with activity at the 5-ht2c receptor |
| CN101712675B (zh) | 2008-10-07 | 2013-07-03 | 江苏恒谊药业有限公司 | 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用 |
| NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| EP2744807A4 (en) | 2011-08-15 | 2015-03-04 | Intermune Inc | COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS |
| US9416139B2 (en) | 2012-11-29 | 2016-08-16 | Sunshine Lake Pharma Co., Ltd. | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof |
| WO2014106800A2 (en) | 2013-01-04 | 2014-07-10 | Aurigene Discovery Technologies Limited | Substituted 2-amino pyrimidine derivatives as kinase inhibitors |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| PE20160664A1 (es) * | 2013-06-27 | 2016-07-09 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina |
| EP3021673A1 (en) | 2013-07-17 | 2016-05-25 | Bayer CropScience Aktiengesellschaft | Heterocyclic sulfonylamino(thio)carbonyl-derivatives with nematicidal properties |
| JP6929857B2 (ja) | 2016-01-15 | 2021-09-01 | ファイザー・インク | 6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド |
-
2017
- 2017-01-09 JP JP2018536264A patent/JP6929857B2/ja active Active
- 2017-01-09 AU AU2017208119A patent/AU2017208119B2/en active Active
- 2017-01-09 BR BR112018013955-6A patent/BR112018013955B1/pt active IP Right Grant
- 2017-01-09 CN CN201780017459.4A patent/CN108884093B/zh active Active
- 2017-01-09 RU RU2018125942A patent/RU2712455C1/ru active
- 2017-01-09 ES ES17700748T patent/ES2837018T3/es active Active
- 2017-01-09 US US16/069,585 patent/US10590128B2/en active Active
- 2017-01-09 WO PCT/IB2017/050094 patent/WO2017122116A1/en not_active Ceased
- 2017-01-09 CA CA3011201A patent/CA3011201C/en active Active
- 2017-01-09 EP EP17700748.1A patent/EP3402796B1/en active Active
- 2017-01-09 MX MX2018008653A patent/MX384569B/es unknown
- 2017-01-09 SG SG11201805202VA patent/SG11201805202VA/en unknown
- 2017-01-09 KR KR1020187023277A patent/KR102206321B1/ko active Active
- 2017-01-13 TW TW106101286A patent/TWI633104B/zh active
-
2018
- 2018-06-07 ZA ZA2018/03776A patent/ZA201803776B/en unknown
- 2018-06-27 IL IL260298A patent/IL260298B/en unknown
-
2020
- 2020-01-23 US US16/750,505 patent/US11390623B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3402796B1 (en) | 2020-11-18 |
| US20190047997A1 (en) | 2019-02-14 |
| IL260298B (en) | 2021-07-29 |
| US10590128B2 (en) | 2020-03-17 |
| TWI633104B (zh) | 2018-08-21 |
| RU2712455C1 (ru) | 2020-01-29 |
| CN108884093A (zh) | 2018-11-23 |
| US11390623B2 (en) | 2022-07-19 |
| JP2019501930A (ja) | 2019-01-24 |
| BR112018013955A2 (pt) | 2018-12-11 |
| CA3011201C (en) | 2020-09-22 |
| KR102206321B1 (ko) | 2021-01-21 |
| CN108884093B (zh) | 2021-07-09 |
| ES2837018T3 (es) | 2021-06-29 |
| BR112018013955B1 (pt) | 2024-01-16 |
| MX2018008653A (es) | 2018-12-10 |
| WO2017122116A1 (en) | 2017-07-20 |
| KR20180100432A (ko) | 2018-09-10 |
| JP6929857B2 (ja) | 2021-09-01 |
| IL260298A (en) | 2018-08-30 |
| ZA201803776B (en) | 2020-09-30 |
| US20200157098A1 (en) | 2020-05-21 |
| AU2017208119A1 (en) | 2018-06-28 |
| AU2017208119B2 (en) | 2019-11-07 |
| CA3011201A1 (en) | 2017-07-20 |
| SG11201805202VA (en) | 2018-07-30 |
| EP3402796A1 (en) | 2018-11-21 |
| TW201736367A (zh) | 2017-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018008653A (es) | Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina . | |
| MX382599B (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina. | |
| UY37311A (es) | Derivados de 5,7-dihidro-pirrolo-piridina | |
| GT201300206A (es) | Imidazo(5,1-f)(1,2,4)triazinas para el tratamiento de transtornos neurológicos | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| UY35129A (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| MX2015011618A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso. | |
| PE20151001A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| DOP2015000009A (es) | Antagonistas del receptor de 5-ht3 | |
| SV2016005306A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| UY36218A (es) | “derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1” | |
| CL2014002847A1 (es) | Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras. | |
| CL2015000559A1 (es) | Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras. | |
| SV2016005305A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| MX2019007100A (es) | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. |